A High Calcium-Phosphate Product Is Associated with High C-Reactive Protein Concentrations in Hemodialysis Patients

Abstract

Background: An elevated Ca×PO₄ product and C-reactive protein (CRP) have been associated with coronary artery calcification and increased cardiovascular mortality in hemodialysis (HD) patients. However, it has not been defined, so far, whether and how both parameters are related to each other. For this reason we have evaluated in a cross-sectional and in an interventional study the possible correlation between Ca×PO₄ and CRP and the effect of the correction of a high Ca×PO₄ on CRP levels. Methods: 47 uremic patients (age 65 ± 16 years) on regular chronic HD were selected from a total population of 125 prevalent patients treated at our Institution. Patients had no clinical evidence of either acute infectious or inflammatory diseases for at least 4 weeks before the study. They were on regular bicarbonate HD for 6–329 months (median 42). CRP, hemoglobin (Hb), serum albumin (sAlb), protein catabolic rate (PCRn), serum calcium (Ca), serum phosphorus (PO₄), Ca×PO₄, intact PTH, Kt/V, presence of ischemic heart disease (IHD) and/or peripheral vascular disease (PVD) were recorded. CRP was Ln-transformed in all statistical analyses because of positive skewness. Results: The main findings were: LnCRP 2.17 ± 0.77 mg/l, Ca 10.1 ± 0.4 mg/dl, PO₄ 5.8 ± 0.6 mg/dl, Ca×PO₄ 59 ± 6 mg²/dl², andPTHint 218 ± 195 ng/ml. 18/47 had IHD, 18/47 PVD. A significant hyperbolic correlation between Ca×PO₄ and CRP was observed. A piecewise linear regression model analysis identified a break-point for Ca×PO₄ at 55 mg²/dl². Comparison of CRP levels after the division of the patients into two groups according to Ca×PO₄ break-point (group A, Ca×PO₄ ≤55 mg²/dl², n = 16 patients; group B, Ca×PO₄ >55 mg²/dl², n = 31 patients) showed that CRP levels were significantly lower in patients in group A (LnCRP 1.43 ± 0.22 mg/l) than in group B (LnCRP 2.55 ± 0.67 mg/l, p < 0.0001). Multiple regression analysis bearing LnCRP as dependent variable confirmed Ca×PO₄ as the most significant variable among the other variables examined. In 22 patients with Ca×PO₄ ≧60 mg²/dl², we performed intensive lowering of the Ca×PO₄ product in order to reach and maintain a Ca×PO₄ ≤55 mg²/dl² for 3 months. At the end of observation, a significant reduction in Ca×PO₄ and LnCRP was observed (Ca×PO₄ pre 62.8 ± 1.9 vs. post 46.3 ± 6.2 mg²/dl²: p < 0.0001; LnCRP pre 2.32 ± 0.36 vs. post 1.83 ± 0.14 mg/l: p < 0.0001). No significant variation in the other biochemical parameters was observed. Conclusions: Our data show that in chronic HD patients in steady clinical conditions with no clinical evidence of either infectious or inflammatory diseases, a high Ca×PO₄ is associated with high CRP concentrations. Intensive lowering of Ca×PO...

Fibroblast Growth Factor 23 and Inflammation in CKD

“…Our results are also consistent with those of prior studies that reported associations between serum phosphate and inflammatory markers in patients with CKD stages 3-4 (25) and those with ESRD (26). These studies did not measure FGF23; however, given the known correlation between elevated phosphate and FGF23 levels, these findings support the link between FGF23 and inflammation that we observed.…”

Relationship between aortic valve sclerosis and left ventricular hypertrophy in chronic haemodialysis patients

“…Valvular calcification has been associated with enhanced inflammation in patients with renal failure [17]. Moreover, a high CaxPO4 product has been related to high C-reactive protein (CRP) levels and valvular calcification in chronic haemodialysis patients [18,19]. We also found higher levels of CRP in AVS patients, suggesting a role for chronic inflammation in the pathogenesis of AVS.…”

Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients

“…However, the inter-relationship between both factors has been scarcely analyzed. Two previous studies in hemodialysis, with a limited number of patients, showed that a high Ca x P was associated with high CRP concentrations (20,21). Consequently, there is a potential basis to speculate that alterations of mineral metabolism may be associated with inflammation in CKD.…”

“…Most previous studies have been performed in hemodialysis, with a limited number of subjects, and with the potentially confounding effect of concomitant treatment with Ca supplements, phosphate binders, or vitamin D derivates (20,21). The aim of this study was to examine the interrelationships among the main parameters of mineral metabolism (Ca, P, Ca x P, and PTH) and inflammation (CRP and IL-6) in patients with advanced CKD.…”